| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Ovarian Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Ovarian Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Adnexal Diseases | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Gonadal Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Ovarian Diseases | |||||
| Urogenital Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| MOv-gamma chimeric receptor gene | |||||
| aldesleukin | |||||
| therapeutic allogeneic lymphocytes | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-HIV Agents | |||||
| Anti-Infective Agents | |||||
| Anti-Retroviral Agents | |||||
| Antineoplastic Agents | |||||
| Antiviral Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| NCI - Center for Cancer Research-Medical Oncology | |||||
| National Cancer Institute (NCI) | |||||
|
